Deal Volume Rose in July
July’s combined transaction total hit 127 deals, up 2% compared with the bang-up month of July 2014, which had 124 transactions. The Services sector had a strong performance, accounting for 60% of deal volume. Long-Term Care made up 27% of the volume overall with 34 announced transactions. That equalled the record set last July for the sector, and will probably break it as more deals come to light. The Managed Care sector posted some extra activity, although seven deals versus two deals the month prior and a year ago isn’t moving the needle very high. July 2015 DealsShare of Total Services Behavioral Health Care32% Home Health & Hospice23% Hospitals76% Labs, MRI & Dialysis43%... Read More »BioClinica Acquires a Patient Recruitment Firm
BioClinica, Inc., a global provider of clinical trial management services, extended its offerings with the acquisition of MediciGroup, Inc., a global patient recruitment and retention firm. The acquisition includes MediciGlobal, Ltd. and Access to Patients, LLC. Medici also provides a lost-to-follow-up patient locate service that finds missing patients globally. BioClinica was taken private for $123 million in January 2013 by a joint venture between JLL Partners, Inc. and Ampersand Partners. As part of that deal, the firms paid an undisclosed amount for medical imaging company CoreLab Partners, Inc. and merged it with BioClinica. Financial terms for the MediciGroup deal were not disclosed.... Read More »Consolidation Continues in the CRO Market
Back in 2013 clinical research organizations (CROs) were hot commodities, with 20 transactions for the year (that’s big, for the CRO sector). That was the summer that Kohlberg Kravis Roberts (NYSE: KKR) acquired PRA International and then ReSearch Pharmaceutical Services. This year, CROs are still in investors’ sites, with seven trasactions announced to date. After visiting a few healthcare deal making conferences recently, we expect to see a few more in the coming months. Read More »Juno Therapeutics Teams up with Celgene
Celgene Corporation (NASDAQ: CELG) made a big bet on a small company last week, when it agreed to pay nearly $1 billion to Juno Therapeutics (NASDAQ: JUNO) for a 10-year collaboration on immunotherapies targeting cancer and autoimmune diseases. The real price is $999,803,496 and consists of an upfront payment of $150 million, and the purchase of 9.1 million shares of JUNO common stock at a price of $93.00 per share. That’s a pretty generous offer, considering Juno’s stock price was bumping along around $54.00 late last week. Juno will be responsible for research and development in North America, and retains commercialization rights there. Celgene will be responsible for development and... Read More »Sabra Buys the NMS Portfolio
Sabra Health Care REIT (NASDAQ: SBRA) plunked down $234 million for four skilled nursing facilities, known as the “NMS Portfolio,” all located in Maryland. The four skilled nursing facilities, with a combined total of 678 beds, specialize in transitional care and medically complex post-surgical, ventilator and dialysis patients. Sabra will enter into a triple-net master lease agreement with the current operator on three of the facilities and a triple-net lease agreement on the fourth, which is encumbered by a HUD loan. They will have an initial term of 15 years, two 10-year renewal options and annual rent escalators equal to the great of 2.50% or CPI, but not to exceed 2.75%. Initial yield... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
